Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E16.90 EPS (ttm)2.42 Insider Own16.40% Shs Outstand2.49B Perf Week1.41%
Market Cap102.19B Forward P/E11.47 EPS next Y3.57 Insider Trans0.00% Shs Float2.21B Perf Month2.76%
Income6.13B PEG3.13 EPS next Q- Inst Own9.70% Short Float0.13% Perf Quarter-6.74%
Sales44.55B P/S2.29 EPS this Y16.10% Inst Trans-1.81% Short Ratio1.47 Perf Half Y-15.93%
Book/sh28.51 P/B1.44 EPS next Y8.18% ROA- Target Price48.00 Perf Year-8.10%
Cash/sh- P/C- EPS next 5Y5.40% ROE- 52W Range38.14 - 50.65 Perf YTD-4.74%
Dividend1.64 P/FCF- EPS past 5Y1.10% ROI7.20% 52W High-19.13% Beta0.88
Dividend %4.00% Quick Ratio1.30 Sales past 5Y0.10% Gross Margin67.90% 52W Low7.39% ATR0.58
Employees106556 Current Ratio1.70 Sales Q/Q-0.50% Oper. Margin- RSI (14)53.22 Volatility1.04% 1.15%
OptionableYes Debt/Eq0.27 EPS Q/Q12.60% Profit Margin- Rel Volume1.07 Prev Close40.55
ShortableYes LT Debt/Eq0.25 EarningsFeb 07 BMO Payout- Avg Volume1.89M Price40.96
Recom2.20 SMA202.61% SMA50-2.24% SMA200-11.07% Volume2,030,383 Change1.01%
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Mar-16-18 09:49AM  The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery Zacks
Mar-15-18 03:06PM  Top Research Report for AT&T, Goldman Sachs & Sanofi Zacks
09:54AM  An Intrinsic Calculation For Sanofi (EPA:SAN) Shows Its 40% Undervalued Simply Wall St.
09:45AM  Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns Zacks
02:01AM  Sanofi successfully prices EUR 8 billion of bond issues GlobeNewswire
Mar-14-18 11:12AM  Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy Zacks
07:00AM  Bull of the Day: Regeneron (REGN) Zacks
Mar-12-18 09:16PM  Regeneron Takes Aim at Amgen and Esperion Therapeutics Motley Fool
04:53PM  How A Strong Trial From Regeneron Pharma Could Help These Rivals Investor's Business Daily
02:12PM  Regeneron Pharma Turnaround Gains Steam Investopedia
01:56PM  Sanofi and Regeneron's Price Gamble Is Worth It Bloomberg
01:38PM  Drugmakers Try a Rare Tactic to Boost Sales: Cutting the Price Bloomberg
12:38PM  Regeneron CEO puts conditions on lowering his $14,000-per-year cholesterol drug CNBC
09:13AM  Regeneron and Sanofi Announce Positive Data on Praluent Zacks
08:53AM  Regeneron discounts on cholesterol drug sends some rival stocks down MarketWatch
08:37AM  In Cholesterol Drug Battle, Sanofi/Regeneron Jolt Prospects Of The Medicines Company And Esperion Forbes
06:16AM  New cholesterol data shows drug reduces cardiac events CNBC Videos
12:29AM  Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage The Wall Street Journal
Mar-10-18 07:18PM  Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate PR Newswire
07:18PM  Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate CNW Group
11:30AM  Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay? Reuters
09:37AM  Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam Reuters
09:03AM  Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need GlobeNewswire
09:02AM  Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate GlobeNewswire
09:02AM  Opposite Day: Drug May Save Lives, So Drugmakers Offer To Cut Price Forbes
09:00AM  Regeneron and Sanofi Plan to Cut Cholesterol Drug Price The Wall Street Journal
09:00AM  The ODYSSEY Trial Ends Well -- But Will It Be Enough? Forbes
09:00AM  Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay? Reuters
09:00AM  Regeneron, Sanofi Cut Heart Drug's Price to Spur Greater Use Bloomberg
09:00AM  Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate PR Newswire
Mar-09-18 07:17AM  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck Zacks
Mar-08-18 05:00PM  M&A, Innovation & New Drugs to Drive Pharma Stocks Zacks
11:57AM  Sanofi may seek U.S. approval for Dengvaxia despite Philippines outrage Reuters
09:01AM  Sanofi Completes Acquisition of Bioverativ Inc. GlobeNewswire
08:19AM  Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta Zacks
08:05AM  Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck Zacks
01:48AM  Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform GlobeNewswire
Mar-07-18 05:13PM  FDA did not issue new statement on vaccines and autism Associated Press
04:00PM  Pharmaceutical Industry Outlook - March 2018 Zacks
02:14PM  Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report GlobeNewswire
12:49PM  Sanofi may seek U.S. approval for Dengvaxia despite Philippines outrage Reuters
Mar-06-18 09:57AM  Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director GlobeNewswire
Mar-05-18 11:00PM  A Frenchman Demands 1.2 Million After Sexting His Assistant Bloomberg
04:35PM  FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma Zacks
Mar-02-18 03:00AM  Novo Nordisk CEO Sees Competition in U.S. Driving Down Prices Bloomberg Video
01:01AM  Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma GlobeNewswire
Mar-01-18 03:23PM  Why Novavax Stock Spiked Today Motley Fool
11:10AM  Activist Alex Denner to gain board control at Medicines Company CNBC
08:47AM  Novavax Shares Rise 30% On Positive Data, But Risks Remain Benzinga
04:01AM  Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx GlobeNewswire
Feb-28-18 12:20PM  4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio InvestorPlace
07:00AM  Scientists Want to Completely Rethink How They Make the Flu Vaccine Bloomberg
Feb-26-18 03:07PM  Philippine FDA Says Sanofi of Knew of Vaccine's Dangers in 2015
Feb-23-18 01:57PM  Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG
12:50PM  China Seizes Anbang Insurance, Owner of Waldorf Astoria: LIVE MARKETS BLOG
11:00AM  BMW to Build EV Minis in China: LIVE MARKETS BLOG
Feb-16-18 01:05PM  Why 2018 Could Be An Explosive Year For Biotech Mergers Investor's Business Daily
12:14PM  Healthcare Stocks In The News Last Week Forbes
06:04AM  Could Novavax, Inc. Be a Millionaire-Maker Stock? Motley Fool
Feb-15-18 03:21PM  The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs Forbes
09:57AM  The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi Zacks
Feb-14-18 05:15PM  Top Research Reports for ExxonMobil, Caterpillar & Union Pacific Zacks
Feb-12-18 04:26PM  CDC Still Recommends Sanofi, GlaxoSmithKline Vaccines As Flu-Related Deaths Rise Benzinga
03:37PM  Alnylam Pharmaceuticals Starts the Wait for Approval Motley Fool
09:37AM  Dont Buy MannKind Corporation Stock Under Any Circumstances InvestorPlace
05:31AM  GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018 Moody's
Feb-09-18 09:54AM  Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates Zacks
06:26AM  L'Oreal ready to buy Nestle stake in cosmetics leader Reuters
04:47AM  L'Oreal ready to buy shareholder Nestle's stake in the firm: CEO Reuters
Feb-08-18 06:48PM  Stock Market Drop Not Seen Dampening Healthcare Deal Activity
11:45AM  Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow Zacks
08:06AM  Regeneron stock lifts 4% after Q4 profit, revenue beats MarketWatch
07:00AM  First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent, now available in Canada CNW Group
05:56AM  Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc. GlobeNewswire
Feb-07-18 04:39PM  Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe Investor's Business Daily
12:36PM  European stocks end with gains, halting 7-day skid MarketWatch
12:20PM  Sanofi (SNY) Q4 2017 Earnings Conference Call Transcript Motley Fool
12:01PM  Sanofi's Deal Desperation Now Looks Even Worse Bloomberg
10:43AM  Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales Zacks
07:58AM  Investors Are Trying to Figure Out the 'Powell Put'
07:49AM  Sanofi's return to profit growth this year slower than hoped Reuters
07:38AM  Sanofi Delivers 2017 Business EPS in line with Guidance PR Newswire
07:27AM  Investors Are Trying to Figure Out the 'Powell Put': Market Recon
06:30AM  Sanofi to Host Earnings Call ACCESSWIRE
05:01AM  Sanofi misses Street 4Q forecasts Associated Press
04:44AM  Sanofi: No proof that vaccine linked to Philippines deaths Associated Press
03:38AM  Drugmaker Sanofi sees return to profit growth this year Reuters
02:42AM  [$$] Sanofi Profit Falls Significantly The Wall Street Journal
01:42AM  Sanofi pins hopes on 2018 for growth after recent takeover deals Reuters
01:40AM  European markets move higher after recent market turmoil; Hexagon rallies 8% CNBC
Feb-06-18 10:16AM  [$$] Buyout Firms Fight it Out for 2 Billion Sanofi Drug Unit The Wall Street Journal
Feb-05-18 01:07PM  Brazil's EMS and India's Torrent Pharma vying for Sanofi's generic drugs - sources Reuters
09:46AM  The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex Zacks
04:50AM  Sanofi rejects Philippine plea for refund on used vaccines Associated Press
Feb-04-18 04:49PM  Why Novavax, Inc. Stock Blasted Off in January Motley Fool
Feb-02-18 02:08PM  An Earnings Miss Ushers in an Era of Stagnation for Amgen, Inc. Stock InvestorPlace
09:23AM  [$$] Initial Philippines Probe Finds 'Causal Association' Between Deaths, Dengue Vaccine The Wall Street Journal
04:41AM  Philippines: 3 deaths may be linked to dengue vaccinations Associated Press
02:10AM  Philippines: 3 deaths may be linked to dengue vaccinations Associated Press
Feb-01-18 08:11PM  Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings? Zacks
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulator and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerAug 25Buy481.3672,37834,840,13323,880,537Aug 29 05:00 PM
Sanofi10% OwnerAug 24Buy482.04105,82051,009,57223,808,159Aug 25 05:00 PM
Sanofi10% OwnerAug 23Buy478.9860,59529,024,05023,702,339Aug 25 05:00 PM
Sanofi10% OwnerJun 02Buy478.17136,05065,055,55823,641,744Jun 06 05:00 PM